+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 70Years
All Genders
ID07595003

Phase 3 Study to Test the Safety and Effectiveness of 4-MUST Tablets for Treating Chronic Cholecystitis and Biliary Dyskinesia

Led by Valenta Pharm JSC · Updated on 2026-05-19

300

Participants Needed

10

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy, safety, and tolerability of 4-MUST, 128 mg tablets compared to placebo in adults with chronic cholecystitis and biliary dyskinesia. This phase 3, multicenter, randomized, double-blind study aims to assess how 4-MUST impacts symptoms related to these gallbladder and biliary tract conditions, including pain and gastrointestinal discomfort. Participants are randomly assigned to receive either 4-MUST tablets or placebo. The 4-MUST group takes three 128 mg tablets orally three times a day, 30 minutes before meals, totaling 1152 mg daily. The placebo group takes identical-appearing tablets on the same schedule. Treatment lasts for approximately 29 days, followed by monitoring until day 36. Throughout the study, participants report pain severity in the upper abdomen using a Visual Analog Scale VAS and complete questionnaires about gastrointestinal symptoms and quality of life. Safety is monitored through physical exams, vital signs, laboratory tests, and electrocardiograms at scheduled visits. Researchers track adverse events and treatment tolerability to evaluate the overall impact of 4-MUST compared to placebo during and shortly after treatment.

CONDITIONS

Brief Title

Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here